Advertisement
UK markets close in 2 hours 14 minutes
  • FTSE 100

    8,280.79
    +43.07 (+0.52%)
     
  • FTSE 250

    20,529.59
    +87.24 (+0.43%)
     
  • AIM

    772.66
    +0.09 (+0.01%)
     
  • GBP/EUR

    1.1801
    -0.0021 (-0.18%)
     
  • GBP/USD

    1.2672
    +0.0026 (+0.21%)
     
  • Bitcoin GBP

    48,159.16
    -2,611.81 (-5.14%)
     
  • CMC Crypto 200

    1,262.41
    -47.31 (-3.61%)
     
  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     
  • DOW

    39,150.33
    +15.53 (+0.04%)
     
  • CRUDE OIL

    80.67
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,339.10
    +7.90 (+0.34%)
     
  • NIKKEI 225

    38,804.65
    +208.18 (+0.54%)
     
  • HANG SENG

    18,027.71
    -0.81 (-0.00%)
     
  • DAX

    18,266.40
    +102.88 (+0.57%)
     
  • CAC 40

    7,691.31
    +62.74 (+0.82%)
     

Olema Oncology to Participate in Upcoming Investor Conferences in June

Olema Oncology
Olema Oncology

SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conferences:

Jefferies Global Healthcare Conference 
Date: Wednesday, June 5, 2024, at 2:00 p.m. ET
Location: Marriott Marquis in New York, NY
Format: Fireside Chat

Goldman Sachs 45th Annual Global Healthcare Conference 
Date: Wednesday, June 12, 2024, at 11:20 a.m. ET
Location: Loews Miami Beach Hotel in Miami, FL
Format: Fireside Chat

ADVERTISEMENT

Live webcasts of the presentations and any accompanying materials will be available under the News & Events section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.

Contact:
Geoffrey Mogilner, Vice President, Investor Relations and Communications
ir@olema.com